Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant
International Journal of Environmental Research and Public Health · 2025
DOI: 10.3390/ijerph22070990 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Environmental Research and Public Health, 2025. Verfasst von Andrew I G McLennan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of Regina, Regina, SK S4S 0A2, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Medical Marijuana, Health Knowledge, Attitudes, Practice, Cannabis. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer patients use cannabis for medicinal purposes; however, few studies have examined hematology patients’ use of cannabis and no research to our knowledge has investigated the use of cannabis amongst hematology patients before and after hematopoietic stem cell transplant (HCT). The purpose of this longitudinal survey study was to assess aspects of cannabis use in patients who underwent HCT. Eligible patients (N = 30) completed two surveys before and 90 days following their HCT. The surveys inquired about several aspects of cannabis (e.g., rate of use, beliefs and attitudes, access to information) and physical and psychological outcomes (e.g., anxiety, comorbidities, graft-versus-host-disease). Rates of cannabis use decreased following HCT (n = 14, 46% to n = 11, 40%). Conversations on cannabis that were initiated by an oncology health care provider increased post-transplant (n = 3, 10% to n = 11, 37%). This coincided with fewer who were smoking cannabis as a primary consumption method (n = 5, 38 to n = 2, 18) and an increase in the use of pharmaceutical cannabinoid products (n = 4, 13% to n = 6, 21%) as well as oils and topicals. Of the total sample, 63% (n = 17) experienced post-treatment complications and 33% (n = 10) developed GVHD, six of whom where recent cannabis users. This study provided insight into cannabis use amongst HCT patients and warrants further research with this population, including more exploration of the relationship between GVHD and cannabis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychology, University of Regina, Regina, SK S4S 0A2, Canada.
- Palliative Care, Arthur J.E. Child Comprehensive Cancer Centre, Alberta Health Services, Calgary, AB T2N 4N2, Canada.
- Pharmacy Services, Arthur J.E. Child Comprehensive Cancer Centre, Alberta Health Services, Calgary, AB T2N 4N2, Canada.
- Department of Radiation Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
ORCID-Profile: Cameron Roessner
Zitieren
APA
McLennan, A. I. G., Booker, R., Roessner, C., & Kerba, M. (2025). Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph22070990
Vancouver
McLennan AIG, Booker R, Roessner C, Kerba M. Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant. International Journal of Environmental Research and Public Health. 2025. doi:10.3390/ijerph22070990
BibTeX
@article{McLennan2025,
author = {McLennan, Andrew I G and Booker, Reanne and Roessner, Cameron and Kerba, Marc},
title = {Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant},
journal = {International Journal of Environmental Research and Public Health},
year = {2025},
doi = {10.3390/ijerph22070990}
}
EUVIMED